Stockcharts.com on the point and figure technical analysis has a price objective of $2.31. That does not seem unreasonable. When you look at a long term chart, HemaCare was consistently in the $2-$3 range without the earnings potential it has today. It seems to be really cheap right now as it completes the recovery from the bad acquisition. That is behind it, however, and the future looks strong.